Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Stage IIIB or IV NSCLC (any histology) at the time of study entry * Histologically or cytologically confirmed diagnosis of NSCLC that is: 1. EGFR wt as per patient standard of care by a validated test 2. AND ALK-negative rearrangement as part of the patient standard of care by a validated test 3. AND (by central assessment) either: * Cohort 1: Pre-treated patients with cMET GCN ≥ 6 or * Cohort 2: Pre-treated patients with cMET GCN ≥4 and \< 6, or * Cohort 3: Pre-treated patients with cMET mutations regardless of cMET GCN, or * Patients must have failed one or two prior lines of systemic therapy for advanced/metastatic disease * At least one measurable lesion as defined by RECIST 1.1 * Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study. * Patients must have adequate organ function * ECOG performance status (PS) of 0 or 1 Details and other protocol-defined inclusion criteria may apply Exclusion Criteria: * Prior treatment with crizotinib, or any other cMET or HGF inhibitor * Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations * Patients with characterized ALK-positive rearrangement * Clinically significant, uncontrolled heart diseases. * Patients receiving treatment with medications that cannot be discontinued at least 1 week prior to first INC280 treatment and for the duration of the study: * Strong and moderate inhibitors of CYP3A4 * Strong inducers of CYP3A4 * Impairment of GI function or GI disease that may significantly alter the absorption of INC280 * Patients receiving treatment with any enzyme-inducing anticonvulsant * Previous anti-cancer and investigational agents within 4 weeks or ≤ 5 x half-life of the agent (whichever is longer) before first dose * Pregnant or nursing women * Women of child-bearing potential, unless they are using highly effective methods of contraception * Sexually active males unless they use a condom during intercourse Other protocol-defined exclusion criteria may apply